Concepts (192)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Asthma | 17 | 2021 | 150 | 1.970 |
Why?
|
| Immunoglobulin G | 8 | 2022 | 70 | 1.310 |
Why?
|
| Antibodies, Viral | 5 | 2022 | 44 | 1.180 |
Why?
|
| Immunoglobulins, Intravenous | 4 | 2018 | 15 | 0.920 |
Why?
|
| Antibody Formation | 2 | 2022 | 14 | 0.910 |
Why?
|
| Salivary alpha-Amylases | 1 | 2023 | 3 | 0.800 |
Why?
|
| Vaccines | 1 | 2022 | 7 | 0.780 |
Why?
|
| Viral Vaccines | 1 | 2022 | 1 | 0.780 |
Why?
|
| Immunologic Deficiency Syndromes | 3 | 2017 | 7 | 0.750 |
Why?
|
| Agammaglobulinemia | 2 | 2018 | 2 | 0.710 |
Why?
|
| Common Variable Immunodeficiency | 2 | 2018 | 5 | 0.710 |
Why?
|
| Bacterial Infections | 3 | 2018 | 52 | 0.680 |
Why?
|
| Genetic Diseases, X-Linked | 1 | 2018 | 1 | 0.570 |
Why?
|
| Immunoglobulins | 1 | 2017 | 12 | 0.540 |
Why?
|
| Child, Preschool | 12 | 2019 | 578 | 0.540 |
Why?
|
| Immunologic Factors | 1 | 2017 | 19 | 0.530 |
Why?
|
| Humans | 37 | 2023 | 23331 | 0.530 |
Why?
|
| Immunotherapy | 1 | 2017 | 50 | 0.530 |
Why?
|
| Fluticasone | 4 | 2019 | 4 | 0.490 |
Why?
|
| Child | 12 | 2021 | 1171 | 0.470 |
Why?
|
| Biomarkers | 4 | 2023 | 487 | 0.460 |
Why?
|
| Adrenal Cortex Hormones | 5 | 2019 | 100 | 0.430 |
Why?
|
| Glucocorticoids | 4 | 2019 | 60 | 0.420 |
Why?
|
| Precision Medicine | 3 | 2021 | 24 | 0.380 |
Why?
|
| Respiratory Sounds | 2 | 2019 | 9 | 0.360 |
Why?
|
| Female | 21 | 2021 | 13124 | 0.350 |
Why?
|
| Bronchodilator Agents | 3 | 2019 | 11 | 0.350 |
Why?
|
| Male | 20 | 2021 | 12629 | 0.350 |
Why?
|
| Adolescent | 9 | 2019 | 1916 | 0.340 |
Why?
|
| Adult | 13 | 2021 | 7070 | 0.340 |
Why?
|
| Salmeterol Xinafoate | 2 | 2019 | 2 | 0.310 |
Why?
|
| Alendronate | 2 | 2019 | 7 | 0.310 |
Why?
|
| Ibuprofen | 2 | 2021 | 11 | 0.300 |
Why?
|
| Young Adult | 6 | 2019 | 1674 | 0.290 |
Why?
|
| NF-kappa B | 3 | 2022 | 107 | 0.280 |
Why?
|
| Double-Blind Method | 9 | 2021 | 382 | 0.280 |
Why?
|
| Middle Aged | 9 | 2021 | 8055 | 0.270 |
Why?
|
| Saliva | 2 | 2023 | 48 | 0.270 |
Why?
|
| Anti-Asthmatic Agents | 4 | 2018 | 31 | 0.250 |
Why?
|
| Administration, Inhalation | 7 | 2019 | 37 | 0.250 |
Why?
|
| Eosinophilia | 2 | 2017 | 35 | 0.210 |
Why?
|
| Cockroaches | 1 | 2003 | 2 | 0.210 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2003 | 4 | 0.210 |
Why?
|
| Allergens | 1 | 2003 | 16 | 0.210 |
Why?
|
| Acetaminophen | 3 | 2021 | 22 | 0.200 |
Why?
|
| Nucleocapsid | 1 | 2022 | 1 | 0.200 |
Why?
|
| Neutralization Tests | 1 | 2022 | 5 | 0.200 |
Why?
|
| Antibodies, Neutralizing | 1 | 2022 | 15 | 0.190 |
Why?
|
| beta-Glucans | 1 | 2022 | 26 | 0.190 |
Why?
|
| Sputum | 2 | 2019 | 21 | 0.190 |
Why?
|
| Health Personnel | 1 | 2022 | 87 | 0.180 |
Why?
|
| Prospective Studies | 4 | 2019 | 1523 | 0.180 |
Why?
|
| Infant | 6 | 2018 | 486 | 0.170 |
Why?
|
| Lung | 2 | 2019 | 153 | 0.170 |
Why?
|
| Education, Medical, Continuing | 1 | 2020 | 30 | 0.160 |
Why?
|
| Adrenergic beta-2 Receptor Agonists | 1 | 2019 | 3 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2021 | 251 | 0.160 |
Why?
|
| Hypersensitivity | 1 | 2020 | 46 | 0.160 |
Why?
|
| Longitudinal Studies | 1 | 2022 | 1050 | 0.160 |
Why?
|
| Tiotropium Bromide | 1 | 2019 | 2 | 0.150 |
Why?
|
| Mometasone Furoate | 1 | 2019 | 7 | 0.150 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 2019 | 3 | 0.150 |
Why?
|
| Betacoronavirus | 1 | 2020 | 68 | 0.150 |
Why?
|
| Eosinophils | 1 | 2019 | 36 | 0.150 |
Why?
|
| Vitamin A Deficiency | 1 | 2018 | 1 | 0.150 |
Why?
|
| Vitamin A | 1 | 2018 | 7 | 0.150 |
Why?
|
| Contrast Sensitivity | 1 | 2018 | 6 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 79 | 0.150 |
Why?
|
| Zinc | 1 | 2018 | 39 | 0.150 |
Why?
|
| Cohort Studies | 2 | 2021 | 1429 | 0.140 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 83 | 0.140 |
Why?
|
| Pandemics | 1 | 2020 | 203 | 0.140 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2018 | 15 | 0.140 |
Why?
|
| HIV Infections | 1 | 2022 | 424 | 0.140 |
Why?
|
| Glutathione | 1 | 2018 | 23 | 0.140 |
Why?
|
| Arginine | 1 | 2018 | 17 | 0.140 |
Why?
|
| Treatment Outcome | 4 | 2018 | 2988 | 0.140 |
Why?
|
| Leukotriene Antagonists | 1 | 2016 | 1 | 0.130 |
Why?
|
| Postoperative Complications | 1 | 2022 | 836 | 0.130 |
Why?
|
| Inhalation Exposure | 2 | 2008 | 5 | 0.130 |
Why?
|
| Sensitivity and Specificity | 3 | 2022 | 452 | 0.120 |
Why?
|
| Azithromycin | 1 | 2015 | 2 | 0.120 |
Why?
|
| Respiratory Tract Infections | 1 | 2015 | 24 | 0.120 |
Why?
|
| Secondary Prevention | 1 | 2015 | 49 | 0.120 |
Why?
|
| Pregnenediones | 1 | 2014 | 3 | 0.110 |
Why?
|
| Vitamins | 1 | 2014 | 14 | 0.110 |
Why?
|
| Cholecalciferol | 1 | 2014 | 6 | 0.110 |
Why?
|
| Vitamin D Deficiency | 1 | 2014 | 10 | 0.110 |
Why?
|
| Recurrence | 3 | 2016 | 272 | 0.110 |
Why?
|
| Quality of Life | 1 | 2017 | 560 | 0.100 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 363 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2019 | 324 | 0.100 |
Why?
|
| Cotinine | 2 | 2011 | 5 | 0.100 |
Why?
|
| Follow-Up Studies | 3 | 2018 | 1441 | 0.090 |
Why?
|
| Dermatitis, Allergic Contact | 1 | 2011 | 5 | 0.090 |
Why?
|
| Pruritus | 1 | 2011 | 10 | 0.090 |
Why?
|
| Silicones | 1 | 2011 | 10 | 0.090 |
Why?
|
| Catheters, Indwelling | 1 | 2011 | 21 | 0.090 |
Why?
|
| Peritoneal Dialysis | 1 | 2011 | 26 | 0.090 |
Why?
|
| Mexican Americans | 1 | 2011 | 27 | 0.090 |
Why?
|
| Aged | 3 | 2018 | 7552 | 0.080 |
Why?
|
| Research Design | 2 | 2021 | 157 | 0.080 |
Why?
|
| Prevalence | 2 | 2018 | 384 | 0.080 |
Why?
|
| Smoking | 1 | 2011 | 168 | 0.080 |
Why?
|
| Cross-Over Studies | 2 | 2019 | 64 | 0.080 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2008 | 6 | 0.070 |
Why?
|
| Leukocyte Count | 2 | 2019 | 61 | 0.070 |
Why?
|
| Albuterol | 2 | 2018 | 15 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2021 | 813 | 0.070 |
Why?
|
| Models, Biological | 1 | 2008 | 306 | 0.060 |
Why?
|
| Cross-Sectional Studies | 3 | 2018 | 774 | 0.060 |
Why?
|
| Quinolines | 1 | 2005 | 8 | 0.060 |
Why?
|
| Acetates | 1 | 2005 | 16 | 0.060 |
Why?
|
| Incidence | 2 | 2018 | 636 | 0.060 |
Why?
|
| Air Pollution, Indoor | 1 | 2003 | 1 | 0.050 |
Why?
|
| Pyroglyphidae | 1 | 2003 | 2 | 0.050 |
Why?
|
| Skin Tests | 1 | 2003 | 7 | 0.050 |
Why?
|
| Urban Health | 1 | 2003 | 20 | 0.050 |
Why?
|
| Cats | 1 | 2003 | 28 | 0.050 |
Why?
|
| Child Welfare | 1 | 2003 | 16 | 0.050 |
Why?
|
| Statistics as Topic | 1 | 2003 | 84 | 0.050 |
Why?
|
| Dogs | 1 | 2003 | 147 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2022 | 403 | 0.050 |
Why?
|
| Sialic Acid Binding Immunoglobulin-like Lectins | 1 | 2023 | 3 | 0.050 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2023 | 5 | 0.050 |
Why?
|
| Hepatitis B e Antigens | 1 | 2022 | 1 | 0.050 |
Why?
|
| Hepatitis B Antibodies | 1 | 2022 | 2 | 0.050 |
Why?
|
| Antibodies | 1 | 2023 | 44 | 0.050 |
Why?
|
| Hepatitis B Surface Antigens | 1 | 2022 | 5 | 0.050 |
Why?
|
| Killer Cells, Natural | 1 | 2023 | 41 | 0.050 |
Why?
|
| Syk Kinase | 1 | 2022 | 12 | 0.050 |
Why?
|
| Lectins, C-Type | 1 | 2022 | 51 | 0.050 |
Why?
|
| Respiratory Syncytial Viruses | 1 | 2002 | 1 | 0.050 |
Why?
|
| Chemokines | 1 | 2002 | 17 | 0.050 |
Why?
|
| Serologic Tests | 1 | 2022 | 8 | 0.050 |
Why?
|
| United States | 2 | 2018 | 1829 | 0.050 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2021 | 20 | 0.050 |
Why?
|
| Advisory Committees | 1 | 2021 | 19 | 0.050 |
Why?
|
| Clinical Protocols | 1 | 2021 | 54 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2002 | 113 | 0.040 |
Why?
|
| Immunization, Passive | 1 | 2021 | 7 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2021 | 18 | 0.040 |
Why?
|
| Immunoglobulin M | 1 | 2021 | 12 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2002 | 177 | 0.040 |
Why?
|
| Inflammation | 1 | 2022 | 235 | 0.040 |
Why?
|
| Administration, Oral | 2 | 2014 | 99 | 0.040 |
Why?
|
| Education, Distance | 1 | 2020 | 15 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2019 | 33 | 0.040 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2019 | 26 | 0.040 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 9 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2021 | 594 | 0.040 |
Why?
|
| Surveys and Questionnaires | 1 | 2003 | 1038 | 0.040 |
Why?
|
| Medication Adherence | 1 | 2019 | 49 | 0.040 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 593 | 0.040 |
Why?
|
| Ornithine | 1 | 2018 | 1 | 0.040 |
Why?
|
| Peak Expiratory Flow Rate | 1 | 2018 | 1 | 0.040 |
Why?
|
| Growth | 1 | 2018 | 6 | 0.040 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2018 | 17 | 0.030 |
Why?
|
| Case-Control Studies | 1 | 2018 | 482 | 0.030 |
Why?
|
| Forced Expiratory Volume | 1 | 2017 | 9 | 0.030 |
Why?
|
| Chicago | 2 | 2011 | 819 | 0.030 |
Why?
|
| Immunoglobulin E | 1 | 2017 | 9 | 0.030 |
Why?
|
| Animals | 1 | 2003 | 3287 | 0.030 |
Why?
|
| Fever | 1 | 2016 | 32 | 0.030 |
Why?
|
| Neutrophils | 1 | 2017 | 94 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2016 | 169 | 0.030 |
Why?
|
| Phenotype | 1 | 2017 | 257 | 0.030 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2015 | 53 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2015 | 153 | 0.030 |
Why?
|
| Disease Progression | 1 | 2015 | 525 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2014 | 129 | 0.030 |
Why?
|
| Pain | 1 | 2016 | 327 | 0.030 |
Why?
|
| Patch Tests | 1 | 2011 | 2 | 0.020 |
Why?
|
| Exanthema | 1 | 2011 | 11 | 0.020 |
Why?
|
| Morbidity | 1 | 2011 | 51 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 220 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2009 | 19 | 0.020 |
Why?
|
| Half-Life | 1 | 2009 | 11 | 0.020 |
Why?
|
| Drug Dosage Calculations | 1 | 2009 | 6 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 2011 | 123 | 0.020 |
Why?
|
| Socioeconomic Factors | 1 | 2008 | 270 | 0.020 |
Why?
|
| Sulfides | 1 | 2005 | 10 | 0.010 |
Why?
|
| Cyclopropanes | 1 | 2005 | 13 | 0.010 |
Why?
|
| Adrenergic beta-Agonists | 1 | 2005 | 15 | 0.010 |
Why?
|
| Placebos | 1 | 2005 | 64 | 0.010 |
Why?
|
| Acetylcysteine | 1 | 2002 | 14 | 0.010 |
Why?
|
| Free Radical Scavengers | 1 | 2002 | 7 | 0.010 |
Why?
|
| Tumor Cells, Cultured | 1 | 2002 | 126 | 0.010 |
Why?
|
| Oxidation-Reduction | 1 | 2002 | 64 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2002 | 34 | 0.010 |
Why?
|
| Antiviral Agents | 1 | 2002 | 66 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 542 | 0.010 |
Why?
|